Copper excess, zinc deficiency, and cognition loss in Alzheimer's disease

In this special issue about biofactors causing cognitive impairment, we present evidence for and discuss two such biofactors. One is excess copper, causing neuronal toxicity. The other is zinc deficiency, causing neuronal damage. We present evidence that Alzheimer's disease (AD) has become an epidemic in developed, but not undeveloped, countries and that the epidemic is a new disease phenomenon, beginning in the early 1900s and exploding in the last 50 years. This leads to the conclusion that something in the developed environment is a major risk factor for AD. We hypothesize that the factor is inorganic copper, leached from the copper plumbing, the use of which coincides with the AD epidemic. We present a web of evidence supporting this hypothesis. Regarding zinc, we have shown that patients with AD are zinc deficient when compared with age‐matched controls. Zinc has critical functions in the brain, and lack of zinc can cause neuronal death. A nonblinded study about 20 years ago showed considerable improvement in AD with zinc therapy, and a mouse AD model study also showed significant cognitive benefit from zinc supplementation. In a small blinded study we carried out, post hoc analysis revealed that 6 months of zinc therapy resulted in significant benefit relative to placebo controls in two cognitive measuring systems. These two factors may be linked in that zinc therapy significantly reduced free copper levels. Thus, zinc may act by lowering copper toxicity or by direct benefit on neuronal health, or both.

[1]  W. Thies,et al.  2013 Alzheimer's disease facts and figures , 2013, Alzheimer's & Dementia.

[2]  A. Warren,et al.  Are hereditary hemochromatosis mutations involved in Alzheimer disease? , 2000, American journal of medical genetics.

[3]  S. Sensi,et al.  Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction , 2010, Cell Death and Disease.

[4]  C. Masters,et al.  Contrasting, Species-Dependent Modulation of Copper-Mediated Neurotoxicity by the Alzheimer's Disease Amyloid Precursor Protein , 2002, The Journal of Neuroscience.

[5]  Sudha Seshadri,et al.  Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease , 2002 .

[6]  Mark A. Smith,et al.  In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease , 2000, Journal of neurochemistry.

[7]  Xudong Huang,et al.  The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. , 1999, Biochemistry.

[8]  C. Masters,et al.  The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I) , 1996, Science.

[9]  P. Pasqualetti,et al.  Longitudinal prognostic value of serum “free” copper in patients with Alzheimer disease , 2009, Neurology.

[10]  S. Brenner Excess of serum copper not related to ceruloplasmin in Alzheimer disease , 2006, Neurology.

[11]  C. Masters,et al.  The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity , 2011, Journal of neurochemistry.

[12]  A. Alzheimer Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .

[13]  I. Biunno,et al.  Transferrin C2 variant does confer a risk for Alzheimer's disease in caucasians. , 2004, Journal of Alzheimer's disease : JAD.

[14]  D. Sparks,et al.  Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Powers,et al.  Copper-mediated LDL oxidation by homocysteine and related compounds depends largely on copper ligation. , 2004, Biochimica et biophysica acta.

[16]  P. Hedera,et al.  Treatment of Wilson disease with ammonium tetrathiomolybdate: IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease. , 2006, Archives of neurology.

[17]  A. Takeda Insight into Glutamate Excitotoxicity from Synaptic Zinc Homeostasis , 2010, International journal of Alzheimer's disease.

[18]  W. Grant Dietary Links to Alzheimer's Disease , 1997 .

[19]  George J. Brewer,et al.  Subclinical Zinc Deficiency in Alzheimer’s Disease and Parkinson’s Disease , 2010, American journal of Alzheimer's disease and other dementias.

[20]  V. Mok,et al.  Serum zinc is decreased in Alzheimer’s disease and serum arsenic correlates positively with cognitive ability , 2010, BioMetals.

[21]  M. Fujishima,et al.  Prevalence and Etiology of Dementia in a Japanese Community , 1992, Stroke.

[22]  J. Schneider,et al.  Dietary copper and high saturated and trans fat intakes associated with cognitive decline. , 2006, Archives of neurology.

[23]  M. Harada,et al.  Wilson disease , 2002, Medical Electron Microscopy.

[24]  H. Nakanishi,et al.  Copper binding properties of a tau peptide associated with Alzheimer's disease studied by CD, NMR, and MALDI-TOF MS , 2006, Peptides.

[25]  D. Alkon,et al.  Oxidation of Cholesterol by Amyloid Precursor Protein and β-Amyloid Peptide* , 2005, Journal of Biological Chemistry.

[26]  S. Freud The Standard Edition of the Complete Psychological Works of Sigmund Freud , 1953 .

[27]  G. Hill,et al.  Treatment of Wilson's Disease with Zinc II. Validation of Oral 64Copper with Copper Balance , 1986, The American journal of the medical sciences.

[28]  A. Bush,et al.  Cognitive Loss in Zinc Transporter-3 Knock-Out Mice: A Phenocopy for the Synaptic and Memory Deficits of Alzheimer's Disease? , 2010, The Journal of Neuroscience.

[29]  W. Boyd A text-book of pathology : an introduction to medicine , 1943 .

[30]  P. Pasqualetti,et al.  Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF β-amyloid, and h-tau , 2006, Neurology.

[31]  G. Barbati,et al.  Is cognitive function linked to serum free copper levels? A cohort study in a normal population , 2010, Clinical Neurophysiology.

[32]  A. Aisen,et al.  Worsening of neurologic syndrome in patients with Wilson's disease with initial penicillamine therapy. , 1987, Archives of neurology.

[33]  Henpy Kimpton A Textbook of Pathology: An Introduction to Medicine , 1933, The Indian Medical Gazette.

[34]  J. Brunberg,et al.  Treatment of Wilson's disease with zinc: XV long-term follow-up studies. , 1998, The Journal of laboratory and clinical medicine.

[35]  D. Thiele,et al.  Ctr1 drives intestinal copper absorption and is essential for growth, iron metabolism, and neonatal cardiac function. , 2006, Cell metabolism.

[36]  J. Constantinidis Treatment of Alzheimer's disease by zinc compounds , 1992 .

[37]  W. Gowers,et al.  A Manual of Diseases of the Nervous System , 1887, Edinburgh Medical Journal.

[38]  Jonathan D. Smith,et al.  Apolipoprotein E allele–specific antioxidant activity and effects on cytotoxicity by oxidative insults and β–amyloid peptides , 1996, Nature Genetics.

[39]  D. Sparks,et al.  Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. , 2006, The journal of nutrition, health & aging.

[40]  D J Foley,et al.  Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging Study. , 1996, JAMA.

[41]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.